ArticleJournal of the American Academy of Dermatology2025
riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma.
Article in Journal of the American Academy of Dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Prognostic Factors in Primary Head and Neck Cutaneous Squamous Cell Carcinoma: A Large-Scale, Multi-Institutional Competing-Risks Analysis.Journal of surgical oncology · 2026Article
- Beyond Clear Margins: Oncologic Risk and Reconstructive Planning in Head and Neck Cutaneous Squamous Cell Carcinoma-A Structured Narrative Review.Reports (MDPI) · 2026Review
- Leveraging Foundation Models for Histological Grading in Cutaneous Squamous Cell Carcinoma using PathFMTools.Proceedings of machine learning research · 2026Article
- Performance of Staging Systems for Non-head and Neck Cutaneous Squamous Cell Carcinoma.American journal of clinical dermatology · 2026Article
- Perioperative Systemic Therapy for High-Risk Cutaneous Squamous Cell Carcinoma.American journal of clinical dermatology · 2026Review
- Comparative Analysis of Clinical, Dermoscopic, and Confocal Microscopy Scores for Assessing Severity of Actinic Keratosis.Cancers · 2025Article
- Enhanced metastasis risk prediction in cutaneous squamous cell carcinoma using deep learning and computational histopathology.NPJ precision oncology · 2025Article
- Prognostication System for Squamous Cell Carcinoma Using Retrieval Augmented Generation-Enabled Large Language Model.JAMA dermatology · 2025Article
- Mohs Micrographic Surgery and Improved Survival in Skin Cancer: A Narrative Review.Dermatology and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundCutaneous squamous cell carcinoma (CSCC) is a prevalent disease for which improved risk stratification strategies are needed.
objectiveTo develop a novel prognostic model (herein "riSCC") for CSCC and compare riSCC performance to Brigham and Women's Hospital and American Joint Committee on Cancer Staging eighth edition T staging systems.
methodsRetrospective 12-center, multinational cohort study of CSCCs from 1991 to 2023. Clinical and pathologic risk factors, treatments, and outcomes were collected. Fine-Gray model was employed for each outcome with inverse probability of treatment weighting. A final model was trained for prospective use and estimation of hazard ratios.
resultsTwenty-three thousand one hundred sixty-six localized CSCC tumors were included. riSCC prognostic model performed superiorly to American Joint Committee on Cancer eighth edition and Brigham and Women's Hospital T staging for all outcomes. At 5 years, the C-index for riSCC ranged from 0.74 for local recurrence to 0.87 for disease specific death. LIMITATIONS: Retrospective study design.
conclusionriSCC prognostic model offers fine-grained risk estimates and improved stratification for important CSCC outcomes compared to T staging systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.